BG-68501-101 (NCT06257264) is a first-in-human, Phase 1a/1b, open-label, dose-escalation and expansion trial evaluating BG-68501, a selective CDK2 inhibitor, as monotherapy and in combination with fulvestrant with or without BGB-43395 in patients with advanced, nonresectable, or metastatic solid tumors, including HR+/HER2- breast cancer.
Disease State: Breast cancer
BGB-43395-101 (NCT06120283) is a Phase 1a/1b, open-label, dose-escalation and expansion trial of BGB-43395, a selective CDK4 inhibitor, as monotherapy and in combination with fulvestrant, letrozole, or elacestrant in patients with hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer and other advanced solid tumors.
BG-68501-101 (NCT06257264) is a first-in-human, Phase 1a/1b, open-label, dose-escalation and expansion trial evaluating BG-68501, a selective CDK2 inhibitor, as monotherapy and in combination with fulvestrant with or without BGB-43395 in patients with advanced, nonresectable, or metastatic solid tumors, including HR+/HER2- breast cancer.
BGB-43395-101 (NCT06120283) is a Phase 1a/1b, open-label, dose-escalation and expansion trial of BGB-43395, a selective CDK4 inhibitor, as monotherapy and in combination with fulvestrant, letrozole, or elacestrant in patients with hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer and other advanced solid tumors.